亚太子宫癌治疗和诊断市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

亚太子宫癌治疗和诊断市场按癌症类型(子宫内膜腺癌、腺鳞癌、乳头状浆液性癌、子宫肉瘤)、产品和地理细分。

市场快照

Uterine Sarcoma Market Trends
Study Period: 2018 - 2026
Base Year: 2021
CAGR: 2.5 %
Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market Key Players

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

预计亚太子宫癌治疗和诊断市场在预测期内的复合年增长率为 2.5%。推动亚洲地区市场增长的主要因素是对子宫疾病及其可用疗法的认识不断提高、医疗保健支出的增加和药物开发的创新以及随后的技术进步。

据澳大利亚癌症协会估计,2016 年,澳大利亚约有 527 人死于子宫癌。2019 年,估计约有 562 人死亡。此外,它还表示,女性死于子宫癌的风险为 205 分之 1。

此外,政府正在某些亚太地区开展宣传计划。随着政府和医疗保健提供者的关注度不断提高,表明市场将在预测期内快速增长。

Scope of the report

As per the scope of the report, uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. The Asia-Pacific Uterine Cancer Therapeutics & Diagnostics Market is segmented by type of cancer, product, and geography.

By Cancer Type
Endometrial Adenocarcinoma
Adenosquamous Carcinoma
Papillary Serous Carcinoma
Uterine Sarcoma
By Product
Therapeutics
Surgery
Immunotherapy
Radiation Therapy
Chemotherapy
Other Therapeutics
Diagnostics
Biopsy
Pelvic Ultrasound
Hysteroscopy
Dilation and Curettage
CT Scan
Geography
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific

Report scope can be customized per your requirements. Click here.

主要市场趋势

预计子宫内膜腺癌将在亚太子宫癌治疗和诊断市场的预测期内实现最高增长

推动该细分市场增长的主要因素是子宫内膜腺癌的负担不断增加。例如,根据澳大利亚癌症协会的数据,2019 年,据估计,澳大利亚的子宫癌年龄标准化发病率约为每 100,000 名女性 20 例。预计子宫癌的发病率会随着年龄的增长而增加,在 65-69 岁年龄组达到峰值。

此外,根据《妇科肿瘤学杂志 2020》,子宫内膜癌是日本妇科恶性肿瘤患者中发病率最高的主要妇科恶性肿瘤。在日本,2017 年子宫内膜癌的年龄调整死亡率为 2.0。此外,在澳大利亚,根据澳大利亚癌症协会,2019 年诊断出约 3,115 例(4.7%)子宫癌新病例。因此,由于上述因素,预计该细分市场将在未来几年出现增长。

Uterine Sarcoma Market Size

Asia Pacific Uterine Cancer Therapeutics & Diagnostics Market Growth

竞争格局

亚太子宫癌治疗和诊断市场具有综合竞争力,大多数与该市场打交道的公司都是全球参与者。然而,随着技术的不断进步,小公司也开始关注市场渗透,并努力抢占足够的市场份额。参与该市场的一些公司包括默克公司、卫材公司、雅培实验室、F. Hoffmann-La Roche Ltd、武田制药有限公司、西门子医疗保健公司、葛兰素史克公司和诺华公司。

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Awareness About Uterine Diseases and Their Available Therapies

      2. 4.2.2 Increasing Health Care Expenditure

      3. 4.2.3 Innovation in Drug Development and Subsequent Technological Advancements

    3. 4.3 Market Restraints

      1. 4.3.1 Low Success Rate in Clinical Trials for Cancer Drugs

      2. 4.3.2 High Cost Associated With the Treatment

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Cancer Type

      1. 5.1.1 Endometrial Adenocarcinoma

      2. 5.1.2 Adenosquamous Carcinoma

      3. 5.1.3 Papillary Serous Carcinoma

      4. 5.1.4 Uterine Sarcoma

    2. 5.2 By Product

      1. 5.2.1 Therapeutics

        1. 5.2.1.1 Surgery

        2. 5.2.1.2 Immunotherapy

        3. 5.2.1.3 Radiation Therapy

        4. 5.2.1.4 Chemotherapy

        5. 5.2.1.5 Other Therapeutics

      2. 5.2.2 Diagnostics

        1. 5.2.2.1 Biopsy

        2. 5.2.2.2 Pelvic Ultrasound

        3. 5.2.2.3 Hysteroscopy

        4. 5.2.2.4 Dilation and Curettage

        5. 5.2.2.5 CT Scan

    3. 5.3 Geography

      1. 5.3.1 Asia-Pacific

        1. 5.3.1.1 China

        2. 5.3.1.2 Japan

        3. 5.3.1.3 India

        4. 5.3.1.4 Australia

        5. 5.3.1.5 South Korea

        6. 5.3.1.6 Rest of Asia-Pacific

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Merck & Co., Inc

      2. 6.1.2 Eisai.Co.Ltd

      3. 6.1.3 Abbott Laboratories

      4. 6.1.4 F. Hoffmann-La Roche Ltd

      5. 6.1.5 Takeda Pharmaceutical Company Limited

      6. 6.1.6 Siemens Healthcare Inc

      7. 6.1.7 GlaxoSmithKline Plc

      8. 6.1.8 Novartis AG

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The APAC Uterine Cancer Therapeutics & Diagnostics Market market is studied from 2018 - 2026.

The APAC Uterine Cancer Therapeutics & Diagnostics Market is growing at a CAGR of 2.5% over the next 5 years.

Merck & Co., Inc, Eisai.Co.Ltd, Abbott Laboratories, F. Hoffmann-La Roche Ltd, Takeda Pharmaceutical Company Limited are the major companies operating in APAC Uterine Cancer Therapeutics & Diagnostics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!